NRX Pharmaceuticals (NRXP) Stock: Buy, Sell, or Hold?
NRXP - NRX Pharmaceuticals, Inc. Common Stock
$2.91
0.05 (1.93%)
▲
5d:
-3.01%
30d:
-16.04%
90d:
-26.36%
HOLD
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 13, 2026
Get Alerted When NRXP Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: NRXP shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: NRXP shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
In-depth Analysis How we analyze
Valuation Analysis: NRXP is currently trading at $2.90, which is considered oversold relative to its 30-day fair value range of $3.07 to $3.54. From a valuation perspective, the stock is trading at a discount (Forward PE: -8.3) compared to its historical average (9.4). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, NRXP is in a downtrend. The price is currently testing key support at $2.82. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: NRXP scores 68/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $38.50 (+1225.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, NRXP is in a downtrend. The price is currently testing key support at $2.82. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: NRXP scores 68/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $38.50 (+1225.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$3.07 -
$3.54
Company Quality Score
57/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
95.2%
Protect Your Profits
Holding NRXP? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (68/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 1225.3% below Wall St target ($38.50)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- CAUTION: Bottoming setup, but lagging the sector by 29% over 20 days — wait for relative strength
Trading Range Analysis
30-Day Trading Range
$3.07 -
$3.54
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$2.82
Resistance Level
$3.39
Current Trend
Downtrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-8.30
Wall Street Target
$38.50
(+1225.3%)
PE vs Historical
-8.3 vs 9.4
CHEAP
Share & Embed Analysis
Last updated: October 03, 2026 12:59 PM ET
Data refreshes hourly during market hours. Next update: 1:59 PM
Data refreshes hourly during market hours. Next update: 1:59 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NRXP showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$92 | 46 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$109 | 76 BUY |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$34 | 65 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 42 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$128 | 56 HOLD |
Advanced NRXP Option Strategies
Professional options setups generated by AI based on today's NRXP price and gamma walls.
